论文部分内容阅读
目的分析探讨联合用药治疗充血性心力衰竭的临床疗效和安全性。方法回顾性分析2010年9月至2011年9月期间在我院治疗的51例充血性心力衰竭患者的临床资料。将51例患者随机分为观察组26例和对照组25例,观察组行常规方法与美托洛尔联合治疗,对照组行内科常规治疗,疗程15周,对比分析两组治疗前后的超声心动图及6min步行距离。结果用药15周后,观察组的心功能改善明显、左心室射血分数和6min步行距离增加均较对照组明显,两组比较差异有统计学意义(P<0.05)。结论美托洛尔联合常规治疗可极大改善慢性CHF患者的心脏功能,且安全性好,可在临床上广泛应用。
Objective To analyze the clinical efficacy and safety of combination therapy in the treatment of congestive heart failure. Methods The clinical data of 51 patients with congestive heart failure treated in our hospital from September 2010 to September 2011 were retrospectively analyzed. Fifty-one patients were randomly divided into observation group (n = 26) and control group (n = 25). The observation group was treated with metoprolol combined with metoprolol. The control group was treated with routine medicine for 15 weeks. The echocardiography Figure and 6min walking distance. Results After 15 weeks of treatment, the heart function of the observation group improved obviously. The left ventricular ejection fraction and the 6-minute walk distance were significantly higher than those in the control group. There was significant difference between the two groups (P <0.05). Conclusion Metoprolol combined with conventional treatment can greatly improve the cardiac function in patients with chronic CHF, and is safe and can be widely used clinically.